Original title: Scientists reverse brain aging, with a nasal spray
Article
Scientists at Texas A&M describe an intranasal therapy using extracellular vesicles derived from human iPSC neural stem cells that they say reduced multiple markers of neuroinflammation in the hippocampus of 18- to 20.5-month-old mice after only two doses and was associated with better cognitive performance in object-recognition and environment-change tests. The treatment was delivered through the nasal route to bypass the blood-brain barrier and appear to act by EV microRNAs, especially miRNA-30e-3p and miRNA-181a-5p, which are linked to dampening NLRP3 inflammasome and cGAS-STING signaling, lowering oxidative stress, and supporting mitochondrial respiratory gene expression. The authors also report decreased astrocyte hypertrophy and microglial clustering and describe effects that persisted for months in their preclinical model. They reported similar outcomes in male and female mice, filed a U.S. patent, and suggested future applications beyond aging, including possible support for stroke recovery and broader neurodegenerative disease therapy. The write-up presented the results in dramatic language about reversing brain aging and long-term societal impact, while the paper citation indicates publication in the Journal of Extracellular Vesicles and explicitly anchors the work to late-middle-aged mouse physiology rather than human trials.
Readers repeatedly distinguished between lowered inflammation and true rejuvenation, arguing that the headline overstates the study by implying age reversal. Several commenters appreciated the mechanistic detail in the cited abstract, noting the focus on NLRP3, cGAS-STING, microglial transcriptomics, and miRNA-specific pathway effects. Multiple people flagged that the evidence is confined to C57BL/6J mice, so translation to humans remains unproven, while others pointed to the study as interesting despite limited scope and unclear baseline expectations. Some participants contrasted the claim with prior anecdotal approaches like NAC, and a few injected humor or skepticism about hype, dosage routes, or real-world misuse. A separate thread raised ethical concerns about assumptions in human tissue sourcing in related aging research, but the posted study itself is centered on an animal model. Overall, the comments treat the finding as technically promising but premature to market and sensitive to overclaiming.